• Title/Summary/Keyword: 정신약물학

Search Result 106, Processing Time 0.019 seconds

DEVELOPMENTAL PSYCHOPHARMACOLOGY - DEVELOPMENTAL PHARMACOKINETICS, PHARMACODYNAMICS AND PHARMACOGENETICS - (발달학적 정신약물학 - 발달학적 약동학, 약역학 및 약물유전학 -)

  • Cho, Soo-Churl
    • Journal of the Korean Academy of Child and Adolescent Psychiatry
    • /
    • v.14 no.2
    • /
    • pp.157-173
    • /
    • 2003
  • The history of pediatric psychopharmacology is very short and the research on safety, efficacy and side effects is preliminary and long-term effect on growth and maturation is not well known yet. Clinical findings have shown that the responses to antidepressants, antipsychotics, CNS stimulants and steroids in children and adolescents might be different from adult populations. Based on these findings, this paper reviewed three issues, Firstly, in developmental pharmacokinetics. the author discussed the developmental factors affecting drug absorption, distribution, protein-binding, metabolism and excretion. Secondly, in developmental pharmacodynamics, developmental characteristics of dopamine, serotonin, norepinephrine receptors and their clinical implications were reviewed. Lastly, in pharamcogenetic part, the clinical utility of pharmacogenetics, pharmacokinetic aspects of pharmacogenetics, the pharmacodynamic aspects of pharmacogenetics, the association studies of dopamine-related alleles in neuropsychiatric disorders such as attention-deficit hyperactivity disorders or Tourette’s disorders, pharmacogenetic studies dopamine-related alleles and the pharmacogenetic studies of serotonin-related alleles. Based on these preliminary research, future pharmacogenetic applications in childhood and adolescent psychiatry were also discussed.

  • PDF

Neuropsychiatric Aspects of Pulmonary Disease (호흡기 질환의 신경정신과적 측면)

  • Nam, Beom-Woo
    • Korean Journal of Psychosomatic Medicine
    • /
    • v.17 no.2
    • /
    • pp.45-51
    • /
    • 2009
  • Pulmonary diseases distress millions of people worldwide. Numerous studies have shown an association between pulmonary disease and psychiatric disorders. Despite this, little is known about the treatment of psychiatric disorder in patients with pulmonary disease. The three main goals of this article are 1) to discuss the major disorders such as asthma, chronic obstructive pulmonary disease, hyperventilation, tuberculosis, lung cancer that most clinicians see in practice, 2) to provide an information about psychiatric treatment such as anxiety, depression, psychosis in pulmonary disease, and 3) to provide some clinically relevant suggestions about pharmacologic interactions between pulmonary and psychotropic drugs.

  • PDF

Current Pharmacogenetics in Psychiatry (정신의학에서의 약물유전학 현황)

  • Kim, Il Bin;Lee, Yu Sang
    • Korean Journal of Biological Psychiatry
    • /
    • v.28 no.1
    • /
    • pp.1-6
    • /
    • 2021
  • Pharmacogenetics is opening a new era of precision medicine in psychiatry. Drug-metabolizing enzymes are characterized by genetic polymorphisms, which render a large portion of variability in individual drug metabolism. Dose adjustment based on pharmacogenetics knowledge is a first step to translate pharmacogenetics into clinical practice. However, diverse factors including cost-effectiveness should be addressed to provide clinical recommendation. To address current challenges in pharmacogenetics testing in psychiatry, this review provides an update regarding genotyping (SNP analysis, array, and next-generation sequencing), genotype-phenotype correlations, and cost-effectiveness. The current updates on pharmacogenetics in psychiatry will provide guidance for both clinician and researchers to have a consensus in harmonizing efforts to advance the pharmacogenetics field in a part of precision medicine in psychiatry.

Non-Pharmacological Interventions for Behavioral and Psychological Symptoms of Neurocognitive Disorder (신경인지장애의 정신행동증상에 대한 비약물학적 개입)

  • Hyun Kim;Kang Joon Lee
    • Korean Journal of Psychosomatic Medicine
    • /
    • v.31 no.1
    • /
    • pp.1-9
    • /
    • 2023
  • Patients with neurocognitive disorder show behavioral psychological symptoms such as agitation, aggression, depression, and wandering, as well as cognitive decline, which puts a considerable burden on patients and their families. For the treatment of behavioral psychological symptoms, patient-centered, non-pharmacological treatment should be used as a first line approach. This paper describes non-pharmacological interventions to manage and treat behavioral psychological symptoms in patients with neurocognitive disorder. In order to control behavioral psychological symptoms such as agitation, depression, apathy, insomnia, and wandering, it is important to identify and evaluate factors such as environmental changes and drugs, and then solve such problems. Non-pharmacological interventions include reassurance, encourage, distraction, and environmental change. It is necessary to understand behavior from a patient's point of view and to approach the patient's needs and abilities appropriately. Reminiscence therapy, music therapy, aroma therapy, multisensory stimulation therapy, exercise therapy, light therapy, massage therapy, cognitive intervention therapy, and pet therapy are used as non-pharmacological interventions, and these approaches are known to improve symptoms such as depression, apathy, agitation, aggression, anxiety, wandering, and insomnia. However, the quality of the evidence base for non-pharmacological approaches is generally lower than for pharmacological treatments. Therefore, more extensive and accurate effectiveness verification studies are needed in the future.

PHARMACOLOGICAL TREATMENT IN PERVASIVE DEVELOPMENTAL DISORDERS (전반적발달장애의 약물치료)

  • Choi, Jin-Sook
    • Journal of the Korean Academy of Child and Adolescent Psychiatry
    • /
    • v.4 no.1
    • /
    • pp.27-38
    • /
    • 1993
  • Pervasive developmental disorder is one of the most severe clinical disorder in child psychiatry and is associated with deviancies in multiple areas of development. Medication does not cure pervasive developmental disorder and its effectiveness is generally nonspecific. But psychopharmacological treatment can be important for some children with pervasive developmental disorder and can make many young autistics more amenable to behavior modification and education. Haloperidol, the most widely studied antipsychotics, was statistically and clinically superior to placebo, and furthermore, was known to facilitate the positive functioning such as, discrimination learning and imitative communication, without side effects. However, administration of haloperidol is associated with drug related dyskinesia, and it warrants the introduction and use of the other novel drugs. Several biochemical studies suggest that subgroups of children with pervasive developmental disorder show hyperserotonemia and increased endogenous opioid level as compared with controls. Psychopharmacological trials were conducted according to these findings(ex : fenfluramine, naltrexone), with mixed results till now. These and another drugs that have been used in children with pervasive developmental disorder and their effectiveness are reviewed.

  • PDF

The Effect of Second-Generation Antipsychotics Administration for 1-Year on the Platelet Activities in Patients With Schizophrenia: Retrospective Study (조현병 환자에서 1년간의 2세대 항정신병약물 지속적 투여가 혈소판 활성도에 미치는 영향: 후향적 연구)

  • Yoon-Seok, Oh;Jong Wook, Lee;Hong-Seok, Oh;Seung-Jun, Kim;Na-Hyun, Lee;Woo Young, Im;Ji-Woong, Kim
    • Korean Journal of Psychosomatic Medicine
    • /
    • v.30 no.2
    • /
    • pp.165-171
    • /
    • 2022
  • Objectives : This study was conducted to investigate the effect of 1-year administration of second-generation antipsychotics (SGAs) on the platelet activity in patients with schizophrenia through a retrospective review of the medical records. Methods : The mean platelet component (MPC) value was used as an index of the platelet activity. The included subjects (N=24) were the patients who were confirmed to have taken SGAs continuously for one year after the first MPC measurement had been performed. The change of MPC was verified through a paired sample t-test. Results : The result revealed that the mean MPC value was significantly decreased from 26.5±1.4 g/dL to 25.6±1.8 g/dL after 1-year administration of SGAs from the time of the first MPC measurement. Conclusions : This study suggests that 1-year administration of SGAs may be related with increased platelet activity, and that close monitoring for risks such as cerebrovascular/cardiovascular or thromboembolic diseases may be necessary during SGAs treatment in clinical practice.

DENTAL CARE FOR PEOPLE WITH A MENTAL HANDICAPS (정신지체인의 치과관리)

  • Lee, Keung-Ho
    • Journal of the korean academy of Pediatric Dentistry
    • /
    • v.33 no.1
    • /
    • pp.149-159
    • /
    • 2006
  • 과거 정신지체는 사회의 불가사의한 것이었으나 현재는 이들의 원인과 병리현상의 이해로 예방과 의학적 관리에 괄목할 만한 발전이 이루어져 왔다. 그러나 이들 정신지체인의 치과관리는 과거와 별다른 변화를 이루지 못한 것이 우리의 현실이다 이들에 관심을 갖고 치료하기 원하는 치과의사들도 아직 진단이나 치료방법에 이용이 제한되어있다 정신지체인 들에게도 정상화 개념을 도입해 보다 나은 건강관리 환경을 이루도록 시대가 바뀌어 가고 있다. 환자의 권리를 보장키 위해 수용시설 입소화. 물리적인 강제치료 등 기존의 일반적인 행위에서 탈피하여 이제는 행동조절의 차원에서 약물이용과 치과적용에 필요한 모든 지식의 습득이 필수적인 것으로 변화되고 있다.

  • PDF

A CASE OF LETHAL CATATONIA IN A 11-YEAR-OLD BOY (11세 남아에서 발생된 치사성 긴장증 1례)

  • Cho, In-Hee;Hong, Sung-Do;Joung, Yoo-Sook
    • Journal of the Korean Academy of Child and Adolescent Psychiatry
    • /
    • v.10 no.1
    • /
    • pp.121-133
    • /
    • 1999
  • Lethal catatonia is one of catatonic spectrum, but it differentiates itself to a separate entity as a syndrome because of its severity and lethality. The prevalence of this disorder may have declined worldwide, coinciding with the advent of modern psychopharmacologic agents and other advances in medical treatment. The patient reported here was an 11-year old boy, showing catatonic excitement and stuporous condition with high fever, autonomic dysfunction and several catatonic symptoms. This is a case of successful treatment by using intensive medical monitoring and conservative treatment in an intensive care unit, combined with pharmacological treatment and electroconvulsive therapy during the early phase of lethal catatonia with mild symptoms.

  • PDF

Risperidone(R 64766)의 제 1상 임상 연구: 일회 경구투여에 따른 약동학 및 내약성 검토

  • 신상구;이경훈;장인진;신재국;정원석
    • Proceedings of the Korean Society of Applied Pharmacology
    • /
    • 1992.05a
    • /
    • pp.56-56
    • /
    • 1992
  • Risperidone은 D$_2$-수용체와 HT$_2$-수용체 차단효과를 동시에 지녀, 차세대 항정신분열증 치료제로의 가능성을 보이고 있는 약물이다. 그러나 risperidone의 주대사가 CYPIID1에 의할 가능성이 시사되고 있다. 본 연구에서는 향후 항정신병 치료제의 임상 제 1상 연구의 적정 모형 검토를 위해 risperidone율 모델 약물로 체내 약물의 동태, 내약성 및 약물 유전학적 특성등을 검토하였다. CYPIID1의 대사능을 검정한 12명의 정상 성인(11명: extensive metabolizer, 1명: poor metabolizer)을 대상으로 risperidone 투여 시험(placebo, 1, 2 mg)을 무작위 단일맹검 교차시험으로 시행하였다. 투약후 72시간까지 경시적으로 혈액, 뇨 채취 및 ECG lead II, 혈압/맥박의 변동 등을 측정하고, visual analog scale에 의해 중추신경계 주관적 증상들을 관찰 하였다. 혈장 risperidone 및 그 활성형대사물 9-OH risperidone 및 prolactin 농도는 radioimmunoassay법으로 측정하였다.

  • PDF